Evaluation of the Fetal Response to Intrapartum Digital Fetal Scalp Stimulation to Identify Intrapartum Fetal Hypoxia.
NCT ID: NCT07035028
Last Updated: 2025-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
182 participants
INTERVENTIONAL
2024-01-01
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Upon detection of a suspicious or pathologic cardiotocographic recording, the investigators need to perform an objective verification of fetal well-being.
Currently, fetal scalp blood is the reference test to assess intrapartum fetal hypoxia, according to the protocols of the Spanish Society of Gynecology and Obstetrics.
This procedure lasts about 5 minutes and consists of taking a small sample of the fetal scalp, through a vaginal exploration, the blood is collected in a thin tube and analyzed by a machine in the delivery room obtaining the results in a few minutes.
The investigators emphasize that this test is not part of the study, as long as the monitor is suspicious or pathological, it will be performed according to protocol to objectively assess fetal well-being.
Currently there are studies that support the use of fetal scalp stimulation as an alternative technique to assess intrapartum fetal well-being and predict neonatal outcomes, but they also highlight its limited evidence.
Digital fetal scalp stimulation is a NON-invasive method, as no instrument is required and fetal stimulation is a 30-60 second surface rubbing pressure, which is performed manually, through vaginal exploration, the same technique the investigators use to assess dilation during the labor process.
Each patient will be randomly assigned to a study group:
Experimental group: before the extraction of capillary blood from the fetal scalp, fetal head stimulation will be performed, a technique that poses no risk to the baby. The researchers need the consent of the participants to perform this technique and collect data.
Control group: fetal head stimulation will not be applied, but data from the clinical history necessary for this study will be collected.
In no case will extraordinary or unnecessary tests be performed for participation in this study.
This study will have an Informed Consent document.
This study will be carried out at the Fundación Jiménez Díaz and Zarzuela and will include 182 patients for 24 months.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Fetal Scalp Stimulation Versus Fetal Blood Sampling in Labour
NCT05306756
Prediction of Preterm Delivery with Serial Cervical Length Measurements After Threatened Preterm Labor
NCT05044143
Spontaneous Fetal EEG Recording During Labor
NCT03013569
IMPACTS OF BRAXTON-HICKS CONTRACTIONS ON COMPUTERISED CARDIOTOCOGRAPHY PARAMETERS: A POTENTIAL LINK.
NCT04417296
Modified Intrapartum Sims Position-related Efficiency in Correction of Persistent Foetal OP Positions
NCT02209090
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
CTG patterns are classified into discrete general categories according to four criteria: basal FHR, heart rate variability, presence or absence of FHR accelerations, and decelerations. An example of such a classification system is the 2015 FIGO International Federation of Gynecology and Obstetrics guideline, on which the investigators will base our study. The Spanish Society of Gynecology and Obstetrics defines the registry in normal, suspicious, and pathologic categories. Regardless of the classification system used, abnormal FHR patterns that do not respond to basic intrauterine resuscitation measures require further evaluation of fetal well-being and/or termination of pregnancy, either by cesarean section, assisted vaginal delivery, or spontaneous vaginal delivery.
CTG has a high false-positive rate for fetal compromise (60%) and the studies of Chandraharan et al are gaining momentum, where intrapartum interventions should be based on a thorough understanding of the features observed on the tracing recordings to differentiate normal fetal response to continued stress from the onset of compensation, so that timely action can be taken to avoid hypoxic ischemic encephalopathy and prenatal deaths, while avoiding unnecessary intrapartum interventions to the mother. Cesarean section rates are increasing worldwide, much of that increase is due to primary cesarean sections among nulliparous women due to emergency procedures in labor. Our great challenge is to achieve a reliable test of fetal well-being during labor and to be able to be minimally invasive for both mother and fetus.
When a suspicious or pathologic FHR pattern is detected and immediate delivery is not warranted, further evaluation of fetal well-being is necessary; such second-line evaluations or tests include fetal scalp blood, in Spain Gold standard to identify fetuses with acidosis and reduce the false positive rate of CTG, and digital fetal scalp stimulation. Clinical guidelines support the use of digital fetal scalp stimulation but also note that research evidence is limited. Digital fetal scalp stimulation is the least invasive method, as it does not require instruments; it involves rubbing the surface of the fetal scalp with pressure for 30 to 60 seconds; the response to stimulation should be evident in cardiotocographic patterns over the next 10 minutes, using a 5-minute average. Fetal scalp stimulation should elicit an acceleration of FHR defined as an increase in FHR ≥ 15 bpm for at least 15 seconds or normal FHR variability (5 to 25 bpm), or both. The presence of an acceleration of FHR or an increase in variability (when previously reduced), or both, is interpreted as a positive response, comparable to a normal fetal scalp blood pH result greater than 7.20.
Fetal scalp blood sampling is an intrapartum procedure to assess the presence and degree of fetal acidemia by analyzing fetal capillary blood for pH or lactate, as both give similar results, with pH being the gold standard test for fetal acidosis in our setting. An amnioscope with a light source is used to expose the fetal scalp, which is cleaned with a 2% aqueous chlorhexidine gauze from blood, mucosa and amniotic fluid, then the scalp is punctured with a 2 mm blade. The blood is collected in long capillary tubes. The test requires the cervix to be dilated at least 2 to 3 cm, can be difficult to perform and may be uncomfortable for the laboring woman. It is contraindicated when the mother is known to have a serious transmissible infection, such as HIV or hepatitis, and in fetuses at increased risk of hemorrhage. Rare complications described in case reports include infection, hemorrhage and cerebrospinal fluid leakage. The procedure will result in stimulation of the fetus, but the primary intent is to collect a scalp blood that will allow quantitative analysis of fetal pH or lactate, reflecting fetal blood oxygenation.
It is not taken into account that the scalp skin is a nonessential peripheral tissue that undergoes catecholamine-induced vasoconstriction early in the fetal stress response and therefore fetal scalp blood sampling does not reflect oxygenation of the fetal central organs and alkaline amniotic fluid and bile acids from meconium may alter results. It has also been shown that fetal scalp blood has no significant effect on the cesarean section rate in women monitored by continuous cardiotocography. Intrapartum fetal scalp blood sampling to measure pH, base excess or deficit, or lactate has not been clearly demonstrated to reduce emergency cesarean deliveries or operative vaginal deliveries or to improve long-term perinatal outcome.
For this reason and many others, such as quality control problems, cost, patient discomfort, sample failure rates of up to 10% and the lack of availability of sampling kits, fetal scalp blood sampling is only rarely performed in the United States and other countries, which is not currently the situation in Spain, since for the SEGO it continues to be the gold standard for detecting fetal acidosis.
The NICE 2022 guideline conducted a review comparing fetal blood sampling with digital fetal scalp stimulation and noted that the studies conducted to date were of low to very low quality, similar to the Cochrane 2023 review which includes two studies Hughes 2022 and Tahmina 2022 , in which Hughes compares fetal scalp stimulation and cardiotocographic patterns with fetal scalp blood samples and cardiotocographic patterns and Tahmina compares fetal head stimulation and cardiotocographic patterns with no fetal head stimulation intervention. The Hughes study reported an apgar score of less than 7 at 5 minutes, a finding that was not recorded in Tahmina, which reported a lower risk of cesarean section in the fetal scalp stimulation group, but again both studies are of very low quality. Although not included in the NICE or Cochrane review, there are other studies that demonstrate that the effectiveness of fetal scalp stimulation is poor for ruling out or confirming fetal hypoxia during labor.
Therefore, very low certainty evidence is available that makes it unclear whether fetal scalp stimulation is a safe and effective way to confirm fetal well-being during labor. Current studies have limitations. More high quality studies with sufficient sample size are needed to evaluate this research question. There is an ongoing study (FIRSST) that will be added to the NICE review in a later update.
The current project aims to give value to a second tier test with little demonstrated scientific evidence, fetal scalp stimulation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
digital fetal scalp stimulation dFSS
Digital fetal scalp stimulation will be performed for a period of 30 seconds prior to obtaining the fetal blood sample. Digital fetal scalp stimulation will be performed by vaginal touch with a gauze pad and applying rubbing pressure over the fetal scalp for 30 to 60 seconds. This procedure will be recorded on the same RCTG. The FHR pattern on the cardiotocographic recording is closely monitored for 1 to 10 minutes, using a 5-minute mean, following fetal stimulation the fetus should respond with an acceleration of FHR defined as an increase in FHR ≥ 15 bpm (beats per minute for at least 15 seconds or normal FHR variability (5 to 25 bpm), or both. The presence of an acceleration of FHR or an increase in variability when it was previously reduced, or both, is interpreted as a positive response, comparable to a normal fetal blood scalp sample FBS result.
Digital fetal scalp stimulation dFSS
Digital fetal scalp stimulation will be performed for a period of 30 seconds, prior to obtaining the fetal blood sample. Digital fetal scalp stimulation will be performed by vaginal touch with a gauze pad and rubbing the fetal scalp with pressure for 30 to 60 seconds.
NO digital fetal scalp stimulation dFSS
The fetal blood sampling will be performed, since in our environment it is the gold standard method included in the SEGO recommendations.
There is NO intervention.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Digital fetal scalp stimulation dFSS
Digital fetal scalp stimulation will be performed for a period of 30 seconds, prior to obtaining the fetal blood sample. Digital fetal scalp stimulation will be performed by vaginal touch with a gauze pad and rubbing the fetal scalp with pressure for 30 to 60 seconds.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Cephalic presentation.
Gestational age greater than or equal to 37 weeks.
Pathological cardiotocographic record according to the criteria published by FIGO and with indication to perform a second-line complementary test, in our case a gold standard test of fetal scalp blood FBS, which confirms or not if there is a risk of loss of fetal well-being and the need for fetal extraction.
Signature of HIP and CI for data collection.
Exclusion Criteria
Contraindication for FBS
Uterine dilatation that does not make FBS possible.
HIV
Hepatitis
Fetuses at increased risk of hemorrhage.
18 Years
50 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CEU San Pablo University
OTHER
Hospital Universitario Sanitas La Zarzuela
OTHER
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Raquel Maqueda Moreno
Investigator name
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
JAVIER PLAZA ARRANZ, Doctor
Role: STUDY_DIRECTOR
Hospital Fundación Jiménez Diaz
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fundación Jimenez Diaz Y Hospital La Zarzuela
Madrid, , Spain
Hospital Universitario Sanitas La Zarzuela
Madrid, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
ACOG Practice Bulletin No. 106: Intrapartum fetal heart rate monitoring: nomenclature, interpretation, and general management principles. Obstet Gynecol. 2009 Jul;114(1):192-202. doi: 10.1097/AOG.0b013e3181aef106. No abstract available.
Murphy DJ, Shahabuddin Y, Yambasu S, O'Donoghue K, Devane D, Cotter A, Gaffney G, Burke LA, Molloy EJ, Boland F. Digital fetal scalp stimulation (dFSS) versus fetal blood sampling (FBS) to assess fetal wellbeing in labour-a multi-centre randomised controlled trial: Fetal Intrapartum Randomised Scalp Stimulation Trial (FIRSST NCT05306756). Trials. 2022 Oct 4;23(1):848. doi: 10.1186/s13063-022-06794-9.
Shakouri F, Iorizzo L, Edwards HMK, Vinter CA, Kristensen K, Isberg PE, Wiberg N. Effectiveness of fetal scalp stimulation test in assessing fetal wellbeing during labor, a retrospective cohort study. BMC Pregnancy Childbirth. 2020 Jun 5;20(1):347. doi: 10.1186/s12884-020-03030-7.
Tahmina S, Daniel M, Krishnan L. Manual fetal stimulation during intrapartum fetal surveillance: a randomized controlled trial. Am J Obstet Gynecol MFM. 2022 Mar;4(2):100574. doi: 10.1016/j.ajogmf.2022.100574. Epub 2022 Jan 17.
Al Wattar BH, Lakhiani A, Sacco A, Siddharth A, Bain A, Calvia A, Kamran A, Tiong B, Warwick B, MacMahon C, Marcus D, Long E, Coyle G, Lever GE, Michel G, Gopal G, Baig H, Price HL, Badri H, Stevenson H, Hoyte H, Malik H, Edwards J, Hartley J, Hemers J, Tamblyn J, Dalton JAW, Frost J, Subba K, Baxter K, Sivakumar K, Murphy K, Papadakis K, Bladon LR, Kasaven L, Manning L, Prior M, Ghosh M, Couch M, Altunel M, Pearce M, Cocker M, Stephanou M, Jie M, Mistry M, Wahby MO, Saidi NS, Ramshaw NL, Tempest N, Parker N, Tan PL, Johnson RL, Harris R, Tildesley R, Ram R, Painuly R, Cuffolo R, Bugeja R, Ngadze R, Grainger R, Gurung S, Mak S, Farrell S, Cowey S, Neary S, Quinn S, Nijjar SK, Kenyon S, Lamb S, Tracey S, Lee T, Kinsella T, Davidson T, Corr T, Sampson U, McQueen V, Smith WP, Castling Z; AB-FAB study group. Evaluating the value of intrapartum fetal scalp blood sampling to predict adverse neonatal outcomes: A UK multicentre observational study. Eur J Obstet Gynecol Reprod Biol. 2019 Sep;240:62-67. doi: 10.1016/j.ejogrb.2019.06.012. Epub 2019 Jun 15.
Carbonne B, Pons K, Maisonneuve E. Foetal scalp blood sampling during labour for pH and lactate measurements. Best Pract Res Clin Obstet Gynaecol. 2016 Jan;30:62-7. doi: 10.1016/j.bpobgyn.2015.05.006. Epub 2015 Jul 8.
Chandraharan E, Wiberg N. Fetal scalp blood sampling during labor: an appraisal of the physiological basis and scientific evidence. Acta Obstet Gynecol Scand. 2014 Jun;93(6):544-7. doi: 10.1111/aogs.12416.
Chandraharan E. Should national guidelines continue to recommend fetal scalp blood sampling during labor? J Matern Fetal Neonatal Med. 2016 Nov;29(22):3682-5. doi: 10.3109/14767058.2016.1140740. Epub 2016 Feb 24.
Tahir Mahmood U, O'Gorman C, Marchocki Z, O'Brien Y, Murphy DJ. Fetal scalp stimulation (FSS) versus fetal blood sampling (FBS) for women with abnormal fetal heart rate monitoring in labor: a prospective cohort study. J Matern Fetal Neonatal Med. 2018 Jul;31(13):1742-1747. doi: 10.1080/14767058.2017.1326900. Epub 2017 May 19.
Hughes O, Murphy DJ. Comparing second-line tests to assess fetal wellbeing in Labor: a feasibility study and pilot randomized controlled trial. J Matern Fetal Neonatal Med. 2022 Jan;35(1):91-99. doi: 10.1080/14767058.2020.1712704. Epub 2020 Jan 12.
East CE, Leader LR, Sheehan P, Henshall NE, Colditz PB, Lau R. Intrapartum fetal scalp lactate sampling for fetal assessment in the presence of a non-reassuring fetal heart rate trace. Cochrane Database Syst Rev. 2015 May 1;2015(5):CD006174. doi: 10.1002/14651858.CD006174.pub3.
Troha N, Razem K, Luzovec U, Lucovnik M. Comparison of Four Intrapartum Cardiotocography Classifications for Predicting Neonatal Acidemia at Birth. J Pregnancy. 2023 Feb 13;2023:5853889. doi: 10.1155/2023/5853889. eCollection 2023.
Alfirevic Z, Devane D, Gyte GM, Cuthbert A. Continuous cardiotocography (CTG) as a form of electronic fetal monitoring (EFM) for fetal assessment during labour. Cochrane Database Syst Rev. 2017 Feb 3;2(2):CD006066. doi: 10.1002/14651858.CD006066.pub3.
Murphy DJ, Devane D, Molloy E, Shahabuddin Y. Fetal scalp stimulation for assessing fetal well-being during labour. Cochrane Database Syst Rev. 2023 Jan 10;1(1):CD013808. doi: 10.1002/14651858.CD013808.pub2.
Jia YJ, Chen X, Cui HY, Whelehan V, Archer A, Chandraharan E. Physiological CTG interpretation: the significance of baseline fetal heart rate changes after the onset of decelerations and associated perinatal outcomes. J Matern Fetal Neonatal Med. 2021 Jul;34(14):2349-2354. doi: 10.1080/14767058.2019.1666819. Epub 2019 Sep 18.
Related Links
Access external resources that provide additional context or updates about the study.
Fetal monitoring in labour
SEGO DOCUMENTOS DE CONSENSO 2007.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PIC005-24_FJD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.